In summary, we propose that the enhanced levels of the ligand 7α, 25‐OHC could bind and activate EBI2 to reduce the expression of IFN‐I and ISGs, thus protecting SLE patients. This evidence concerns the gene GPR183 and systemic lupus erythematosus.